Winrevair (sotatercept-csrk) significantly reduced the risk of death, lung transplant, or hospitalization in people with PAH.
A new study published in JCI Insight suggests that interleukin-7 (IL-7), a key immune-boosting cytokine, may help critically ...
Access to a webcast of the presentation will be available on the “Investors” page of Liquidia’s website at https://liquidia.com/investors/events-and-presentations. An archived, recorded version of the ...
Main pulmonary artery diameter is a prognostic indicator in patients with pulmonary arterial hypertension without congenital heart disease.
MedPage Today on MSN1d
Sotatercept Helps the Sickest Patients With Pulmonary Arterial HypertensionAdding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients ...
Sotatercept, an activin signaling inhibitor, was associated with improved outcomes in patients with advanced pulmonary ...
Marc Humbert, M.D., Ph.D., professor of respiratory medicine at Université Paris-Saclay and Inserm, believes that recent ...
In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension ...
The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback